Low-Dose Naltrexone: What to Expect Week by Week in Your First Month

By HealthRX.com Editorial Team

Published Jan 28, 2025Updated Sep 29, 2026Last reviewed Jan 28, 2025

10 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

First-month goal / compare tolerability and useful daily function with your starting point
Dose changes / follow the prescriber's written plan, without automatic weekly increases
Progress / track symptoms, sleep and daily activities using the same measures each week
Formulation / check the pharmacy label for the exact strength and measuring instructions
Important interaction / disclose all opioid medicines before the first dose
Follow-up / agree when to reassess, what improvement would matter and when to stop or change treatment

What LDN means

Naltrexone blocks opioid receptors. Manufactured oral tablets are used for alcohol dependence and opioid blockade as part of an appropriate treatment program. Prescribing much smaller doses for conditions such as fibromyalgia is a separate, off-label practice. The approved tablet label does not establish an LDN treatment schedule for those conditions. Current naltrexone prescribing information.

Fibromyalgia trials have studied doses including 4.5 mg and 6 mg daily. Follow the starting dose and adjustment schedule on your own prescription.

LDN is commonly supplied through compounding. Ask the pharmacist to confirm the strength, ingredients, measuring instructions if it is a liquid, storage and beyond-use date. Do not improvise a low dose by dividing a 50 mg tablet into many small pieces. Compounded LDN formulations are not FDA-approved finished products. FDA compounding questions and answers.

Before the first dose: make the trial measurable

Write down what you and your prescriber are trying to improve. For chronic pain, useful examples include a daily pain score, sleep quality and a specific activity that symptoms limit. Choose an activity that matters to you, such as preparing a meal or completing a work shift, rather than relying only on whether you feel vaguely better.

Keep the same simple record throughout the month:

Record	What to include
Prescription	Dose taken, time and any missed dose
Target symptom	The same rating scale each day
Function	What you could do and what symptoms prevented
Tolerability	Sleep changes, nausea, headache or other new symptoms
Context	Illness, other medicine changes or an unusually demanding day

Record other treatment or routine changes alongside symptoms, then review the pattern at the follow-up date agreed with your prescriber.

Week 1: check instructions and tolerability

Use the prescribed dose. Check that the pharmacy label matches the plan you discussed, especially if the formulation is a liquid or the concentration changes between refills.

Nausea, headache, dizziness and sleep problems are among the effects reported with naltrexone. Record new symptoms and ask the prescriber or pharmacist about troublesome effects rather than automatically increasing the dose. If dizziness affects you, avoid driving or other tasks that require alertness until you know how you respond. MedlinePlus naltrexone information.

Vivid dreams have also been reported in LDN trials. Report sleep disruption so the prescriber can review the dose, timing and treatment plan.

Week 2: review what changed before changing the dose

Compare your notes with the first week. Are sleep problems becoming more disruptive? Is nausea interfering with meals? Are you functioning better, worse or about the same?

Dose escalation, staying at the same dose or changing administration time should follow the plan agreed with the prescriber. Base adjustments on the written prescription and the symptoms recorded in your log.

Week 3: review symptom and activity patterns

Review several days together instead of treating one good or bad day as decisive. Consider whether any change is large enough to matter in daily life and whether side effects offset it.

Bring the pattern to your prescriber, including days with improvement, unchanged symptoms and side effects. Agree on any dose change before making it.

Week 4: make an explicit continue, change or stop decision

The first-month review should cover both possible benefit and burden. Useful questions include:

Has the symptom or activity we chose improved meaningfully?
Are side effects, sleep disruption or costs outweighing any improvement?
Have other changes made the result difficult to interpret?
If we continue, what is the next review date and stopping rule?
Is an established treatment being delayed while we try LDN?

At the month-one appointment, agree whether to continue, adjust or stop, and set the next review date. Persistent side effects or lack of useful improvement should be part of that decision.

Fibromyalgia: results from randomized trials

Trials have tested different doses and follow-up periods. Here are the results from three randomized studies.

Study	Dose and participants	Results
Younger and colleagues, 2013	A small crossover trial in 31 women, using 4.5 mg daily	Reported greater pain reduction during LDN than placebo in the crossover comparison.
Bruun and colleagues, published online 2023	99 women randomized to 6 mg daily or placebo for 12 weeks	Pain decreased in both groups. The between-group difference was not statistically significant, so the trial did not establish superiority for pain relief.
INNOVA, 2026	98 women randomized to 4.5 mg daily or placebo, with follow-up through 12 months	The primary pain outcome at three months did not favor LDN significantly. The study did not demonstrate clinically meaningful improvement over placebo in pain-related outcomes.

Sources: Younger trial, FINAL trial full paper, INNOVA primary publication.

Treatment reviews should focus on symptom scores, daily function and side effects, the outcomes that matter to the person taking the medicine.

LDN research in Crohn's disease, MS and hypothyroidism

Research findings differ by condition and by the outcome measured.

Crohn's disease: early pilot work generated interest. A randomized trial published in September 2026 enrolled 41 adults and stopped early for futility. It did not demonstrate clinical or endoscopic benefit after 12 weeks. A fatigue finding requires further study and does not establish remission or justify replacing effective Crohn's treatment. Van de Pol and colleagues, 2026.

Multiple sclerosis: an eight-week pilot crossover study had 80 participants enrolled and 60 completing it. Some mental health quality-of-life measures improved, but dropout and data problems reduced statistical power. This is not evidence that LDN prevents relapses or replaces disease-modifying therapy. Cree and colleagues, 2010.

Hypothyroidism: a Norwegian before-and-after prescription study of 898 people found no reduction in thyroid hormone use after LDN initiation. It measured dispensing, not a randomized clinical response, but it does not support a general promise that LDN will reduce thyroid replacement needs. Do not change levothyroxine on that assumption. Raknes and Småbrekke, 2020.

Opioids, urgent symptoms and other safety questions

Tell the prescriber about all pain, cough and diarrhea medicines, including tramadol, as well as methadone or buprenorphine. Naltrexone can block opioid effects and precipitate severe withdrawal in someone who is opioid-dependent. A low-dose prescription is not a reason to ignore that interaction.

The standard label recommends at least 7 to 10 opioid-free days for patients previously dependent on short-acting opioids and warns that vulnerability can persist for up to two weeks after methadone or buprenorphine. The prescriber must manage the transition from opioid treatment to naltrexone. Tell surgical and emergency teams that you take naltrexone; never try to overcome its blockade with extra opioids. Prescribing information.

Discuss liver disease, kidney disease, pregnancy, breastfeeding and other medicines before treatment. Seek prompt medical care for yellowing skin or eyes, dark urine or severe abdominal pain. New suicidal thoughts need urgent help. Ask your clinician which monitoring is appropriate for your history rather than following a universal LDN laboratory schedule. MedlinePlus safety information.

Common questions

Does no improvement after a month mean LDN has failed?

Use the month-one review to compare symptoms, daily function and side effects with your starting point. Your prescriber can then agree on continuing, adjusting or stopping treatment.

Is 4.5 mg the correct dose for everyone?

No. Studies have used different doses, including 4.5 mg and 6 mg daily. Use the dose on your own prescription and agree on adjustments with the prescriber.

Do vivid dreams mean LDN is working?

No. A side effect does not demonstrate a therapeutic effect. Report disruptive sleep changes and discuss the dosing plan rather than treating them as a required stage of treatment.

Can I use LDN instead of my established treatment?

Do not replace prescribed thyroid hormone, Crohn's treatment, MS therapy or an opioid-use-disorder treatment based on LDN claims. Discuss any proposed change with the clinician managing that condition.